Skandinaviska Enskilda Banken (SEB)
TVTX icon

Skandinaviska Enskilda Banken (SEB)’s Travere Therapeutics TVTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-74,900
Closed -$1.68M – 738
2016
Q3 		$1.68M Buy
+74,900
New +$1.43M 0.02% 517

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s TVTX Position: Q4 2016 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 74,900 shares — an estimated $1.68M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in TVTX in Q3 2016 and held it in 1 quarter. The position peaked at $1.68M in Q3 2016. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 74,900 Travere Therapeutics shares in Q4 2016, an estimated $1.68M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Travere Therapeutics in Q3 2016 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Travere Therapeutics position peaked at $1.68M in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2016, filed 14 Feb 2017.